



Viral Epidemiology Snapshot: December 12-18, 2021

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	717	51	7.1%
Flu B	717	0	0.0%
RSV	608	39	6.4%
CoV-2 PUI	3179	541	17.0%
CoV-2 Surveillance	729	22	3.0%


Flu A Subtyping

2009 H1N1	0
Seasonal H1	0
Seasonal H3	30
No Subtype	21
Pending subtype	0

Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	602	47	7.8%
Coronavirus 229E	602	2	0.3%
Coronavirus HKU1	602	0	0.0%
Coronavirus NL63	602	0	0.0%
Coronavirus OC43	602	24	4.0%
Metapneumovirus	602	104	17.3%
Rhinovirus/Enterovirus	602	155	25.7%
Parainfluenza 1	602	0	0.0%
Parainfluenza 2	602	7	1.2%
Parainfluenza 3	602	14	2.3%
Parainfluenza 4	602	6	1.0%

Flu, RSV, & CoV-2 Trends




This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning valley laboratories.

As of 11/14, this report also includes Point-of-Care tests (POCT) for influenza performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

CoV-2 Positivity Rate Trends



Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of 10/31, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.

